Trial Profile
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Retinal detachment
- Focus Pharmacokinetics; Therapeutic Use
- 10 Jul 2014 New trial record